Bazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. In late 2013, Pfizer received approval for bazedoxifene as part of the combination drug DUAVEE in the prevention (not treatment) of postmenopausal osteoporosis. It is approved in the Europea...
用于预防和治疗妇女绝经后的骨质疏松症。
Hanyang University, Seoul, Korea, Republic of
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Gabinete Médico Velázquez, Madrid, Spain
Instituto Palacios, Madrid, Spain
Instituto de Ginecología EGR, Madrid, Spain
Pfizer Investigational Site, New Haven, Connecticut, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.